On May 26, 2022 Nippon Kayaku reported (Press release, Nippon Kayaku, MAY 26, 2022, View Source net/doc/4272/ir_material_for_fiscal_ym8/118573/00.pdf [SID1234615059])

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

1. Consolidated Business Results for the Fiscal Year Ended March 31, 2022 (April 1, 2021–March 31, 2022) (Figures shown are rounded down to the nearest million yen.)

(1) Consolidated Operating Results
(2) Consolidated Financial Position
(3) Status of Consolidated Cash Flows

3. Consolidated Business Results Forecasts for the Fiscal Year Ending March 31, 2023 (April 1, 2022– March 31, 2023)
1. Non-consolidated Business Results for the Fiscal Year Ended March 31, 2022 (April 1, 2021–March 31, 2022)
(1) Non-consolidated Operating Result

1. Overview of Operating Results, Financial Position, and Future Outlook
(1) Overview of Operating Results for the Fiscal Year Ended March 31, 2022 In this fiscal year (April 1, 2021 to March 31, 2022), the global economy saw economic activity begin to return to normal and signs of economic recovery, due in part to progress on vaccinations for the novel coronavirus (COVID-19).

However, the impacts of the semiconductor shortage and the automobile industry production cuts, caused by difficulty in procuring parts during the COVID-19 pandemic in Southeast Asia, were exacerbated in Japan and overseas. In the functional chemicals business, the need for semiconductor materials is increasing as rapid advances in digital technology lead to higher performance high-speed (5G) communications devices and other digital equipment, and increasingly sophisticated electronic equipment in vehicles.

The global trends in energy and resource conservation are also creating demand for development of new environmentally friendly materials and recycling technology. In the pharmaceuticals industry, we contribute to extending the healthy lifespan of people in Japan through innovative drug development while ensuring a stable supply of high quality pharmaceuticals. We must do this to pass on a society to the next generation where all people in Japan can be assured of receiving quality medical care. Nippon Kayaku must swiftly and consistently engage in pharmaceutical research, development, manufacturing, and supply to meet these expectations. The automotive industry saw a rebound from the slump in global demand caused by the global spread of the novel coronavirus, with the exception of a few regions. However, the pace of overall automobile production decelerated from the second quarter into the third quarter, owing to the impact of the semiconductor shortage. It is still unclear when the pandemic will end and the failure to resolve the global shortage of parts has also slowed the speed of recovery in automobile production subsequently.

Amid these conditions, the Nippon Kayaku Group worked to implement the key themes and resolve the mid-and long-term key issues outlined in "KAYAKU Next Stage," the mid-term business plan launched in the fiscal year ended March 31, 2020, while also making active use of flextime, telecommuting, and other systems to accommodate the restrictions on corporate activity. We took these steps to ensure the safety of employees working in the Company and at Group companies while also promoting efficient workstyles aimed at minimizing the impact on our business. As a result, consolidated net sales for the fiscal year ended March 31, 2022 totaled 184,805 million yen, an increase of 11,423 million yen (6.6%) year-on-year. Sales outperformed the previous fiscal year in all of the businesses. Consolidated operating income totaled 21,050 million yen, an increase of 5,856 million yen (38.5%) year-on-year, outperforming the previous fiscal year in all businesses. Consolidated ordinary income totaled 23,154 million yen, an increase of 6,615 million yen (40.0%) year-on-year, owing to foreign exchange gains.

Profit attributable to owners of parent was 17,181 million yen, an increase of 4,607 million yen (36.6%) year-on-year. Regarding changes in accounting policies, the Company implemented the Accounting Standard for Revenue Recognition (ASBJ Statement No. 29, revised March 31, 2020) and other guidance from the beginning of this consolidated fiscal year. We have therefore used numbers based on calculation methods subject to different standards than in the previous fiscal year. See 3. Consolidated Financial Statements and Notes to Consolidated Financial Statements, (5) Notes to Consolidated Financial Statements (Changes to Accounting Policies) for further details.

On May 25, 2022 CureVac N.V. (Nasdaq: CVAC), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mRNA"), and myNEO N.V., a Belgium-based immunotherapy company, reported that they have entered into a research and option agreement (Press release, myNEO, MAY 25, 2022, View Source [SID1234640209]). Under the agreement, both companies aim to identify specific antigens found on the surface of tumors for the development of novel mRNA immunotherapies. To achieve this goal, myNEO will leverage its biological datasets and its integrated machine learning and bioinformatics platform to identify and validate specific antigen targets predicted to elicit a strong immune response.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We are translating our mRNA technology insights and learnings to create value in oncology," said Antony Blanc, Chief Business Officer and Chief Commercial Officer of CureVac. "myNEO’s state-of-theart predictive approach to analyze tumor and normal genetic data inputs from multiple sources, perfectly complements our mRNA technology as we advance the development of novel cancer vaccines. Through this collaboration, we prepare to build a strong pipeline in oncology and accelerate growth beyond our progress in prophylactic vaccines."

myNEO utilizes a broad range of underlying genomic alterations to identify constantly emerging, novel classes of antigens of defined tumor types. The immunogenicity of identified antigens is predicted using proprietary algorithms, machine and deep learning methods and an extensive database containing data on tumor specific mutations. Incorporating new ranking methodologies based on tumor cell antigen processing and presentation allows for selection of antigens with the highest confidence of success for potential clinical testing.

"CureVac is a front-runner in the mRNA technology ecosystem, and its use for the development of therapeutic cancer vaccines has shown great promise," said Cedric Bogaert, Chief Executive Officer and co-founder of myNEO. "We’re convinced that combining our innovative neoantigen target identification and selection methods with mRNA technology holds great potential for immunotherapies, and CureVac was the logical choice for us to further validate this avenue. Supplementing our own developments with this collaboration will allow us to benefit from CureVac’s years of experience and know-how, and to create a significant impact on the immunotherapy domain."

On May 25, 2022 BlueSphere Bio, a T-cell receptor (TCR) T-cell therapy company developing a powerful TCR discovery platform and novel therapeutic candidates for patients with hematologic malignancies and solid tumors, reported that Sawa Ito, M.D., Ph.D., was selected to provide an oral presentation during the 2022 Joint ASTCT + EBMT Basic and Translational Scientific retreat (Press release, BlueSphere Bio, MAY 25, 2022, View Source [SID1234616065]). The retreat is a select gathering limited to 100 attendees focused on basic and translation biology in the field.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The presentation will highlight the capabilities of the company’s TCXpress platform and its ability to rapidly clone TCRs against specific targets from single T cells. This work enabled the discovery of BlueSphere’s first clinical candidate, a TCR T-cell therapy directed against the minor histocompatibility antigen (miHA) HA-1. The company anticipates filing its first IND by the end of 2022. The TCXpress platform has also enabled the discovery of four new TCRs reactive against other relevant miHAs, in addition to HA-1. BlueSphere plans to announce details on these other targets later this year.

Title: High Throughput Cloning Reveals Diverse Properties of anti-HA-1 T Cell Receptors

Presenter: Dr. Sawa Ito, hematologist/oncologist at UPMC Hillman Cancer Center and Assistant Professor, Division of Hematology-Oncology and Department of Immunology at the University of Pittsburgh School of Medicine.

About TCXpress

TCXpress is a proprietary high-throughput and efficient T-cell receptor (TCR) capture, expression and functional screening platform capable of processing thousands of single T cells directly into functionally expressed TCRs within a matter of days, thereby creating extensive libraries without the need for sequencing or TCR gene synthesis.

On May 25, 2022 DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases, reported that it will be participating in the 19th Annual Craig-Hallum Institutional Investor Conference being held virtually on Wednesday, June 1, 2022 (Press release, DiaMedica, MAY 25, 2022, View Source [SID1234615110]). Management will be available to participate in one-on-one meetings. Investors and attendees that would like to schedule a meeting with DiaMedica’s management can contact their Craig-Hallum representative to arrange a meeting.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

On May 25, 2022 ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, reported that the following presentations by Company management at upcoming investor conferences will be webcast (Press release, ImmunoGen, MAY 25, 2022, View Source [SID1234615058]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

William Blair 42nd Annual Growth Stock Conference
June 8 at 11:20am CT / 12:20pm ET
Jefferies Healthcare Conference
June 9 at 9:30am ET
A webcast of each presentation will be accessible through the "Investors and Media" section of the Company’s website, www.immunogen.com. Following the live webcast, a replay will be available at the same location.